<DOC>
	<DOCNO>NCT02815267</DOCNO>
	<brief_summary>This Phase 3 study evaluate efficacy , safety long-term safety topical administration FMX-101 , 4 % minocycline foam treatment moderate-to-severe acne vulgaris .</brief_summary>
	<brief_title>A Study Compare Efficacy Safety Topical Administration FMX-101 Treatment Moderate-to-Severe Acne</brief_title>
	<detailed_description />
	<mesh_term>Acne Vulgaris</mesh_term>
	<mesh_term>Minocycline</mesh_term>
	<criteria>Has facial acne vulgaris : 20 50 inflammatory lesion ( papule , pustule , nodule ) ; 25 100 noninflammatory lesion ( open close comedo ) ; 2 nodule face ; IGA score moderate ( 3 ) severe ( 4 ) Willing use supply nonmedicated cleanser ( Cetaphil Gentle Skin Cleanser ) refrain use acne medication , medicate cleanser , excessive sun exposure , tan booth duration study Acne conglobata , acne fulminans , secondary acne ( chloracne , drug induce acne ) dermatological condition face facial hair ( eg , beard , sideburn , mustache ) could interfere clinical evaluation Sunburn face Severe systemic disease , might interfere conduct study interpretation result . Abnormal baseline laboratory value consider clinically significant Allergy tetracyclineclass antibiotic ingredient study drug Pseudomembranous colitis antibioticassociated colitis</criteria>
	<gender>All</gender>
	<minimum_age>9 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>acne</keyword>
</DOC>